| abstract |
The invention features a polypeptide comprising an extracellular ActRIIa variant. In some embodiments, polypeptides of the invention comprise an extracellular ActRIIa variant fused to an Fc domain monomer or residue. The present invention also relates to diseases or disorders involving bone damage, such as primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, fractures, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteoplastic disorders, treatment- It features a method of using pharmaceutical compositions and polypeptides to treat related bone loss, diet-related bone loss, bone loss associated with treatment of obesity, low gravity-related bone loss or immobility-related bone loss. |